No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
CSL240621P340000
- 1.45
- -2.05-58.57%
15min DelayClose May 31 16:00 ET
1.45High1.45Low
1.45Open3.50Pre Close1 Volume18 Open Interest340.00Strike Price145.00Turnover60.23%IV-19.06%PremiumJun 21, 2024Expiry Date0.00Intrinsic Value100Multiplier19DDays to Expiry1.45Time Value100Contract SizeAmericanOptions Type-0.0559Delta0.0020Gamma288.48Leverage Ratio-0.1638Theta-0.0117Rho-16.13Eff Leverage0.1079Vega
Intraday
- 5D
- 1D
News
$1000 Invested In This Stock 10 Years Ago Would Be Worth $4,900 Today
Carlisle Companies (NYSE:CSL) has outperformed the market over the past 10 years by 6.64% on an annualized basis producing an average annual return of 17.06%. Currently, Carlisle Companies has a marke
Express News | NYSE Order Imbalance 52360.0 Shares on Buy Side
Zacks Industry Outlook Highlights Carlisle, Griffon and ITT
Zacks.com Featured Highlights Include Carlisle Companies, ResMed, Booz Allen Hamilton and CrediCorp
The Trend Of High Returns At Carlisle Companies (NYSE:CSL) Has Us Very Interested
(CSL) - Analyzing Carlisle Companies's Short Interest
Carlisle Companies's (NYSE:CSL) short percent of float has risen 9.27% since its last report. The company recently reported that it has 617 thousand shares sold short, which is 1.65% of all regular sh
Comments
The share price has tracked EPS growth, suggesting market sentiment towards the shares remains steady. The stock's recent performance has improved, with a better one-year total shareholder return than the five-year return. Dividends have enhanced the total shareholder return.
Those Who Invested in Carlisle Companies (NYSE:CSL) Five Years Ago Are up 202%CSL anticipates robust annualized double-digit earnings growth over the medium term, driven by strong patient demand for its immunoglobulins franchise. The company has bounced back from the pandemic's impact on its blood plasma collections.
The positive trends in Carlisle Companies' ROCE and its ability to consistently reinvest in itself make it an attractive investment. Investors are expecting more growth in the future. However, it's important to check if these trends will continue.
The stock is seen as overpriced by valuation models, making it less attractive for purchase. With the company's low likelihood of significant earnings growth, its investment appeal is diminished. Profits could be made if share prices meet realistic values.
Carlisle Companies' growth is praised, but future performance remains key. Dividends have boosted total shareholder return, despite short-term performance being below market. Effective business strategy is expected to continue but investors should note identified risks.
1
Read more